What is Fam-trastuzumab deruxtecan-nxki?

Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate (ADC) consisting of a HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload, an esotecan derivative, via a stable tetrapeptide-based cleavable linker. Trastuzumab is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, including in the metastatic setting, or in the neoadjuvant or adjuvant setting, and who experience disease recurrence during or within six months of completing treatment.

Trastuzumab is also indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 1+ or IHC 2+/ISH-) breast cancer who have previously received chemotherapy in the metastatic setting or who have experienced disease recurrence during or within 6 months of completing adjuvant chemotherapy. Alsoindicated for the treatment of adult patients with unresectable or metastatic cancer whose tumors harbor activatingHER2 (ERBB2) mutations and who have received prior systemic therapy. It is also currently indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received trastuzumab.

Trastuzumab is a new type of injectable anti-cancer drug. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is a strictly controlled drug and its purchase is restricted. The price of Trastuzumab original drug specifications100mg per box sold in Hong Kong may be more than RMB 10,000 (the price may fluctuate due to the exchange rate). There are currently no generics of Trastuzumab on the market. For more specific prices and drug information, please consult a medical consultant.